Eva Blondeaux

1.4k total citations
58 papers, 500 citations indexed

About

Eva Blondeaux is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eva Blondeaux has authored 58 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 23 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eva Blondeaux's work include Breast Cancer Treatment Studies (21 papers), HER2/EGFR in Cancer Research (15 papers) and Advanced Breast Cancer Therapies (14 papers). Eva Blondeaux is often cited by papers focused on Breast Cancer Treatment Studies (21 papers), HER2/EGFR in Cancer Research (15 papers) and Advanced Breast Cancer Therapies (14 papers). Eva Blondeaux collaborates with scholars based in Italy, Belgium and Spain. Eva Blondeaux's co-authors include Matteo Lambertini, Lucia Del Mastro, Francesca Poggio, Claudia Bighin, Chiara Molinelli, Luca Arecco, Marcello Ceppi, Marco Bruzzone, Piero Fregatti and Alessia Levaggi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Eva Blondeaux

51 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Blondeaux Italy	13	272	205	151	133	103	58	500
Nanyan Rao China	12	176 0.6×	56 0.3×	32 0.2×	163 1.2×	55 0.5×	26	373
Piero Fregatti Italy	13	212 0.8×	105 0.5×	51 0.3×	160 1.2×	97 0.9×	54	495
Alessia D’Alonzo Italy	9	136 0.5×	175 0.9×	149 1.0×	67 0.5×	26 0.3×	23	341
Hanne Stensheim Norway	8	574 2.1×	172 0.8×	110 0.7×	117 0.9×	27 0.3×	12	682
Laura L. Holman United States	14	156 0.6×	66 0.3×	325 2.2×	67 0.5×	47 0.5×	60	635
Chiara Molinelli Italy	9	158 0.6×	33 0.2×	20 0.1×	79 0.6×	80 0.8×	30	261
Fiona Nussey United Kingdom	11	173 0.6×	14 0.1×	190 1.3×	71 0.5×	36 0.3×	21	380
Malek M. Safa United States	9	125 0.5×	131 0.6×	11 0.1×	91 0.7×	37 0.4×	26	357
Nelleke Ottevanger Netherlands	10	531 2.0×	96 0.5×	128 0.8×	56 0.4×	38 0.4×	16	662
Caroline C. Billingsley United States	9	147 0.5×	67 0.3×	118 0.8×	112 0.8×	37 0.4×	26	433

Countries citing papers authored by Eva Blondeaux

Since Specialization

Citations

This map shows the geographic impact of Eva Blondeaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Blondeaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Blondeaux more than expected).

Fields of papers citing papers by Eva Blondeaux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Blondeaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Blondeaux. The network helps show where Eva Blondeaux may publish in the future.

Co-authorship network of co-authors of Eva Blondeaux

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Blondeaux. A scholar is included among the top collaborators of Eva Blondeaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Blondeaux. Eva Blondeaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blondeaux, Eva, Francesca Poggio, Alessandra Fabi, et al.. (2025). Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world. ESMO Open. 10(2). 104125–104125. 1 indexed citations

Rossi, Giovanni, Marco Tagliamento, Enrica T. Tanda, et al.. (2025). Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses. ESMO Open. 10(9). 105759–105759.

Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208. 3 indexed citations

Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populations. Cancer Research. 84(9_Supplement). PO4–4. 1 indexed citations

Lambertini, Matteo, Eva Blondeaux, Elisa Agostinetto, et al.. (2024). Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.. Journal of Clinical Oncology. 42(16_suppl). 10503–10503. 1 indexed citations

Molinelli, Chiara, Marco Bruzzone, Eva Blondeaux, et al.. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 213. 115113–115113. 4 indexed citations

Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer. npj Breast Cancer. 10(1). 105–105. 1 indexed citations

Tagliamento, Marco, Marco Bruzzone, Marcello Ceppi, et al.. (2023). 186P Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials. Annals of Oncology. 34. S255–S256. 1 indexed citations

Molinelli, Chiara, Flavia Jacobs, Elisa Agostinetto, et al.. (2023). Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology. 41(16_suppl). 1104–1104. 2 indexed citations

10.

Soldato, Davide, Eva Blondeaux, Marco Bruzzone, et al.. (2023). Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): Individual patient-level analysis from five mammella interGruppo (MIG) and gruppo italiano mammella (GIM) randomized clinical trials (RCTs).. Journal of Clinical Oncology. 41(16_suppl). 12067–12067. 1 indexed citations

11.

Blondeaux, Eva, Luca Arecco, Kevin Punie, et al.. (2023). Germline TP53 pathogenic variants and breast cancer: A narrative review. Cancer Treatment Reviews. 114. 102522–102522. 25 indexed citations

12.

Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2022). Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction. 37(5). 954–968. 61 indexed citations

13.

Parisi, Francesca, Maria Grazia Razeti, Eva Blondeaux, et al.. (2020). Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. Clinical Medicine Insights Oncology. 14. 2282627560–2282627560. 6 indexed citations

14.

Garrone, Ornella, Tommaso Giarratano, Andrea Michelotti, et al.. (2020). 290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial. Annals of Oncology. 31. S358–S358.

15.

Molinelli, Chiara, Lucia Del Mastro, S. Giraudi, et al.. (2020). 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study. Annals of Oncology. 31. S331–S331. 1 indexed citations

16.

Poggio, Francesca, Marcello Ceppi, Matteo Lambertini, et al.. (2017). Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. The Breast. 33. 104–108. 17 indexed citations

17.

Bighin, Claudia, Fabio Puglisi, Lorenzo Gerratana, et al.. (2017). Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study. Annals of Oncology. 28. vi25–vi25. 1 indexed citations

18.

Giraudi, S., Andrea Michelotti, Andrea De Censi, et al.. (2016). Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up. Annals of Oncology. 27. iv61–iv61. 1 indexed citations

19.

Rossi, Giovanni, Roberta Iadarola, Matteo Lambertini, et al.. (2015). The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer. Annals of Oncology. 26. vi8–vi8. 1 indexed citations

20.

Giraudi, S., Matteo Lambertini, Paola Anserini, et al.. (2015). Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial. Annals of Oncology. 26. vi10–vi10. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact